Key result
Review evaluates low-dose rivaroxaban for ischemic stroke prevention in patients with atherosclerosis.
Why the study?
Practical introduction of drugs requires evaluating benefit-risk relationships and identifying clinically significant additional benefits through secondary analyses of randomized controlled trials.
Does low-dose rivaroxaban (2.5 mg 2 times a day) prevent ischemic stroke in patients with atherosclerosis-related cardiovascular diseases and sinus rhythm?
Does low-dose rivaroxaban (2.5 mg 2 times a day) prevent ischemic stroke in patients with atherosclerosis-related cardiovascular diseases and sinus rhythm?
Secondary analyses of randomized trials suggest low-dose rivaroxaban may offer benefits for the prevention of ischemic stroke in patients with atherosclerosis-related cardiovascular diseases and sinus rhythm.
Answers are grounded in this paper and cite their sources.
Should not yet change stroke prevention practice in sinus rhythm; leaves open confirmation via dedicated randomized trials.
Practical introduction of drugs requires determining the relationship between the benefits of its use and adverse effects, as well as identifying clinically significant additional benefits of new treatment approaches by analyzing additional parameters or reanalyzing data of randomized controlled trials. Despite the lack of evidence of such analyzes, they often affect the prospects of using drugs in a particular clinical situation. The article discusses new data on the prospects for the use of low-dose rivaroxaban (2,5 mg 2 times a day), which were obtained not only in initial analyzes, but also secondary analyzes of data obtained in randomized trials involving patients with atherosclerosis-related cardiovascular diseases and sinus rhythm.
No takes yet. Share an insight, caveat, or question.
S. R. Gilyarevskiy (2020) conducted a review in Atherosclerosis-related cardiovascular diseases and sinus rhythm. Rivaroxaban was evaluated on Prevention of ischemic stroke. The article reviews secondary analyses of randomized trials evaluating low-dose rivaroxaban for the prevention of ischemic stroke in patients with atherosclerosis.
Synapse has enriched 10 related papers. Consider them for comparative context: